The pre-seed round was led by EWOR to support the rollout of artificial intelligence music production software.
"We’re building the next era of music creation software, where the role of the musician is creative insight and direction, while the AI Co-Producer handles all technical details. "
Nexus Venture Partners led the seed round to support team expansion and product development.
"We don’t sell a platform; we sell a solution. Our AI agents are paired with humans-in-the-loop to ensure 100% accuracy. Peace of mind doesn’t come from a tool; it comes from a result. That’s why we win against consultants because they don’t just sell software, and neither do we."
Fuel Ventures has backed the seed round to support platform development and market expansion.
"This raise is a major step forward in our journey. We’ve seen huge momentum over the past 12 months, and this investment allows us to push even further, improving our tech, deepening customer relationships, and building the operational backbone to scale with confidence. We’re excited to have Fuel Ventures continuing with us on this path."
Gresham House Ventures has backed the AI-powered marketing analytics platform in a £4.1m growth investment.
"Gresham House Ventures brings a wealth of experience to help us scale at speed. Its backing is a huge vote of confidence in our mission to empower marketers and agencies to make better, data-driven decisions. We’re fired up, ambitious, and ready to take things to the next level with the support and experience of the team at Gresham House Ventures."
The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.
"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."